Hypersensitivity Reactions Secondary to Dupilumab in Two Patients with Moderate to Severe Atopic Dermatitis

Dupilumab is a human monoclonal IgG4 antibody that is widely used to treat atopic dermatitis. Dupilumab was recently FDA approved to treat moderate to severe atopic dermatitis. Here we decribe two cases of patients with moderate to severe atopic dermatitis who developed an acute hypersensitivity reaction within hours of their second dose of dupilumab.